Government News

Wockhardt has received marketing authorization from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for its breakthrough antibiotic ZAYNICH® (Zidebactam/Cefepime). The approval marks a significant milestone for India’s fight against antimicrobial resistance, especially in difficult-to-treat Gram-negative bacterial infections.

The Central Drugs Standard Control Organisation (CDSCO) has issued a public notice clarifying that cosmetic products cannot be used through injections and are not permitted for treatment purposes under Indian law.

The notice, released by the Directorate General of Health Services under the Ministry of Health and Family Welfare, comes amid rising use of aesthetic and beauty procedures in clinics and salons across the country.

Boehringer Ingelheim India Private Limited and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur today signed a Memorandum of Understanding (MoU) to advance pharmaceutical research, education and innovation. The five-year collaboration will create new pathways for researchers and students in Bihar and the wider region to engage with global-standard open science platforms, joint research initiatives and capability-building programmes thus strengthening the talent pipeline for India’s next phase of pharmaceutical innovation.

In a regulatory update aimed at streamlining drug export processes, the Central Drugs Standard Control Organization (CDSCO) has announced the implementation of a Prior Intimation System for Form CT-05 applications. The new system will come into force from April 21, 2026, following amendments introduced under Gazette Notification G.S.R. 50(E).

In a significant step toward easing the regulatory burden on India's retail pharmacy sector, the Drugs Consultative Committee (DCC) at its 68th meeting on 20 March 2026 directed a sub-committee to examine four landmark deregulation proposals. The sub-committee's findings will be placed before the DCC for final deliberation before any rule amendments are made.

In a significant development for India’s pharmaceutical regulatory landscape, the Drugs Technical Advisory Board (DTAB) has reaffirmed its position to include all antimicrobial drugs under the definition of “New Drugs” as per the New Drugs and Clinical Trials Rules, 2019.

The decision was taken during the 93rd meeting of DTAB held on February 16, 2026, at FDA Bhawan, New Delhi, conducted in a hybrid format. The board reviewed and approved the Action Taken Report (ATR) from its previous (92nd) meeting held on April 24, 2025.

India’s drug regulator has issued a public advisory after a consignment of insulin pens manufactured by Sanofi India Limited was reported stolen during transportation, raising concerns about potential risks if the products enter the market through unauthorized channels.